Angel investor
| Role | Organisation | Sources |
|---|---|---|
| No role recorded yet. Gina Rinehart has been mentioned, but not yet attached to an organisation. Know their role? | ||
Every published round Gina Rinehart took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Gina Rinehart has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Gina Rinehart, as distinct from the investments it has made.
Companies Gina Rinehart has backed that another company then bought. An exit for the holding, not a deal Gina Rinehart did.
Stories naming Gina Rinehart. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Arafura, partly owned by renewables critic Gina Rinehart, has finalised financing for its Northern Territory rare earths mine, with $1.2 billion in government support and wind turbine and EV makers as customers.
Arafura Rare Earths, part-owned by renewables critic Gina Rinehart, has locked in financing for its Nolans project, drawing roughly $1.2 billion in Australian and German government support despite her anti-net-zero campaigning.
Vulcan Energy Resources says it has made lithium fit for batteries in Europe using the earth's heat, an important step for its Lionheart project, which targets output for about 500,000 electric vehicles.
Sydney neurotech firm Omniscient has banked a Series C from Gina Rinehart and Will Vicars, funding a push into the United States for its connectomics platform.
Canberra announces up to $840m for Arafura's Northern Territory rare earths project, while Liontown secures $550m in bank debt for its Kathleen Valley mine, with CEFC and Export Finance Australia among lenders.
Profiles Australia's ten wealthiest women from the AFR's new list, alongside Canva's in-progress share sale, a large gift to a global gender-fund vehicle, and one backer's earlier healthtech round.